Data and Insights on JAK Inhibitors in RA From the European League Against Rheumatism (EULAR) Congress 2020

The goal of this activity is to educate physicians on the latest efficacy and safety data on Janus kinase inhibitors presented at The European League Against Rheumatism (EULAR) Congress 2020.

Target Audience

This educational activity is intended for an international audience of US and non-US Rheumatologists, Primary Care Physicians and Orthopaedists & Orthopaedic Surgeons.

Learning Objectives

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest clinical data on Janus kinase (JAK) inhibitors
    • Safety profile of JAK inhibitors for the treatment of rheumatoid arthritis (RA) in clinical practice

Additional Information

Partner: 
Medscape
State Relevance: 
Rhode Island Requirement
Course summary
Available credit: 
  • 0.50 MOC
  • 0.50 AMA PRA Category 1 Credit™
Course opens: 
06/29/2020
Course expires: 
06/29/2021
Rating: 
0

Moderator

Gerd R. Burmester, MD

Professor of Medicine
Department of Rheumatology and Clinical Immunology
Charité – Universitätsmedizin Berlin
Berlin, Germany

Disclosure: Gerd R. Burmester, MD, has disclosed the following relevant financial relationships: 
Served as an advisor or consultant for: Abbvie; Gilead Sciences, Inc.; Lilly; Pfizer
Served as a speaker or a member of a speakers bureau for: Abbvie; Gilead Sciences, Inc.; Lilly; Pfizer

Panelists

Stanley Cohen, MD

Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, Texas, United States

Disclosure: Stanley Cohen, MD, has disclosed the following relevant financial relationships: 
Served as an advisor or consultant for: Abbvie; Gilead Sciences, Inc.; Lilly; Pfizer
Received grants for clinical research from: Abbvie; Gilead Sciences, Inc.; Lilly; Pfizer

Bernard Combe, MD, PhD

Professor of Rheumatology
Head, Department of Rheumatology
Montpellier University Hospital
Montpellier, France

Disclosure: Bernard Combe, MD, PhD, has disclosed the following relevant financial relationships: 
Served as an advisor or consultant for: Abbvie; Gilead Sciences, Inc.; Janssen; Lilly; Novartis; Roche-Chugai
Served as a speaker or a member of a speakers bureau for: Abbvie; Bristol Myers Squibb; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme; Roche-Chugai
Received grants for clinical research from: Novartis; Pfizer

Editor

Stuart Crayford, MSc, LLM

Medical Education Director, Medscape, LLC

Disclosure: Stuart Crayford, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Available Credit

  • 0.50 MOC
  • 0.50 AMA PRA Category 1 Credit™
Please login or register to take this course.

This course is offered through Medscape. To take this course you will be redirected to Medscape's website. You must have an account with Medscape in order to complete this activity. 

Mocingbird continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!